These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 15126075)

  • 21. Candidates for peptide receptor radiotherapy today and in the future.
    Reubi JC; Mäcke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: synthesis and characterization.
    Mansi R; Tesauro D; De Capua A; Fattorusso R; Caracò C; Aloj L; Benedetti E; Morelli G
    Biopolymers; 2004; 76(6):527-34. PubMed ID: 15526334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy.
    Zitzmann S; Mier W; Schad A; Kinscherf R; Askoxylakis V; Krämer S; Altmann A; Eisenhut M; Haberkorn U
    Clin Cancer Res; 2005 Jan; 11(1):139-46. PubMed ID: 15671538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies.
    Cyr JE; Pearson DA; Wilson DM; Nelson CA; Guaraldi M; Azure MT; Lister-James J; Dinkelborg LM; Dean RT
    J Med Chem; 2007 Mar; 50(6):1354-64. PubMed ID: 17315859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.
    O'Brien PJ; Irwin W; Diaz D; Howard-Cofield E; Krejsa CM; Slaughter MR; Gao B; Kaludercic N; Angeline A; Bernardi P; Brain P; Hougham C
    Arch Toxicol; 2006 Sep; 80(9):580-604. PubMed ID: 16598496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
    Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
    Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
    Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the in vitro toxicity of indocyanine green to that of trypan blue in human retinal pigment epithelium cell cultures.
    Gale JS; Proulx AA; Gonder JR; Mao AJ; Hutnik CM
    Am J Ophthalmol; 2004 Jul; 138(1):64-9. PubMed ID: 15234283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear translocation of somatostatin analogs.
    Duncan JR; Anderson CJ; Arano Y
    J Nucl Med; 2001 Mar; 42(3):529-31. PubMed ID: 11337534
    [No Abstract]   [Full Text] [Related]  

  • 30. Radiation toxicity of indium-111-2-mercaptopyridine-N-oxide on HeLa S-3 cells.
    Hong SS; Ford EH; Greenspan B
    Br J Radiol; 1989 May; 62(737):468-72. PubMed ID: 2713606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Letter: Somatostatin.
    JAMA; 1975 Jun; 232(12):1217-9. PubMed ID: 1173379
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice.
    Sun LC; Mackey LV; Luo J; Fuselier JA; Coy DH
    Clin Med Oncol; 2008; 2():491-9. PubMed ID: 21892324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients.
    Reubi JC; Waser B; Cescato R; Gloor B; Stettler C; Christ E
    J Clin Endocrinol Metab; 2010 May; 95(5):2343-50. PubMed ID: 20228164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs.
    Anthony CT; Hughey S; Lyons J; Weiss S; Hornick CA; Drouant GJ; Fuselier JA; Coy DH; Murphy WA; Woltering EA
    J Surg Res; 2004 Jun; 119(1):1-13. PubMed ID: 15126075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiply radioiodinated somatostatin analogs induce receptor-specific cytotoxicity.
    Meyers MO; Anthony CT; Coy DH; Murphy WA; Drouant GJ; Fuselier J; Espenan GD; Maloney TJ; Woltering EA
    J Surg Res; 1998 May; 76(2):154-8. PubMed ID: 9698516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive nuclear translocation of somatostatin analogs.
    Hornick CA; Anthony CT; Hughey S; Gebhardt BM; Espenan GD; Woltering EA
    J Nucl Med; 2000 Jul; 41(7):1256-63. PubMed ID: 10914919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiangiogenic therapy with somatostatin receptor-mediated in situ radiation.
    Gulec SA; Gaffga CM; Anthony CT; Su LJ; O'Leary JP; Woltering EA
    Am Surg; 2001 Nov; 67(11):1068-71. PubMed ID: 11730223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.
    McCarthy KE; Woltering EA; Anthony LB
    Q J Nucl Med; 2000 Mar; 44(1):88-95. PubMed ID: 10932605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
    Krenning EP; Teunissen JJ; Valkema R; deHerder WW; deJong M; Kwekkeboom DJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):146-50. PubMed ID: 16625865
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.